Clinical Trial

INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)

Study acronym: INTREPID
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of sapablursen when added on to current standard of care (SOC) for Polycythemia Vera (PV) therapy. The study will be conducted in three sequential parts (Part 1a blinded treatment, Part 1b open-label treatment, \& Part 2 long-term extension). Participants may receive treatment for up to 156 weeks.
Protocol Amendment History 3 changes
notable Trial sites expanded: 1 -> 5 locations 2026-07-01
critical Recruitment opened 2026-05-09
notable Sponsor changed: Ono Pharmaceutical Co. Ltd -> Ono Pharmaceutical Co., Ltd. 2026-04-19
Trial Details
NCT Number NCT07429266
Lead Sponsor Ono Pharmaceutical Co., Ltd.
Collaborators: Deciphera Pharmaceuticals, LLC
Conditions Polycythemia Vera
Enrollment 250 participants
Start Date 2026-05-25
Primary Completion 2028-09 (estimated)
Study Completion 2031-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-08